Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD

12.355  -0.46 (-3.63%)

Fundamental Rating

5

Taking everything into account, CRMD scores 5 out of 10 in our fundamental rating. CRMD was compared to 198 industry peers in the Pharmaceuticals industry. CRMD has a great financial health rating, but its profitability evaluates not so good. CRMD is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CRMD was profitable.
CRMD had a negative operating cash flow in the past year.
In the past 5 years CRMD always reported negative net income.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of CRMD (-15.09%) is better than 66.16% of its industry peers.
CRMD's Return On Equity of -21.18% is fine compared to the rest of the industry. CRMD outperforms 70.20% of its industry peers.
Industry RankSector Rank
ROA -15.09%
ROE -21.18%
ROIC N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

CRMD's Gross Margin of 92.66% is amongst the best of the industry. CRMD outperforms 95.45% of its industry peers.
CRMD's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CRMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

CRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRMD has been increased compared to 1 year ago.
The number of shares outstanding for CRMD has been increased compared to 5 years ago.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CRMD has an Altman-Z score of 11.82. This indicates that CRMD is financially healthy and has little risk of bankruptcy at the moment.
CRMD has a Altman-Z score of 11.82. This is amongst the best in the industry. CRMD outperforms 90.40% of its industry peers.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.82
ROIC/WACCN/A
WACC9.85%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.39 indicates that CRMD has no problem at all paying its short term obligations.
CRMD has a Current ratio (3.39) which is comparable to the rest of the industry.
A Quick Ratio of 3.16 indicates that CRMD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.16, CRMD is in the better half of the industry, outperforming 60.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.16
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 123.66% over the past year.
Measured over the past years, CRMD shows a very strong growth in Revenue. The Revenue has been growing by 174.29% on average per year.
EPS 1Y (TTM)123.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 52.64% on average over the next years. This is a very strong growth
Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 48.61% on average per year.
EPS Next Y346.76%
EPS Next 2Y159.5%
EPS Next 3Y101.76%
EPS Next 5Y52.64%
Revenue Next Year265.42%
Revenue Next 2Y136.58%
Revenue Next 3Y90.53%
Revenue Next 5Y48.61%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 56.16 indicates a quite expensive valuation of CRMD.
Compared to the rest of the industry, the Price/Earnings ratio of CRMD indicates a somewhat cheap valuation: CRMD is cheaper than 79.29% of the companies listed in the same industry.
CRMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.60.
With a Price/Forward Earnings ratio of 7.91, the valuation of CRMD can be described as very cheap.
88.89% of the companies in the same industry are more expensive than CRMD, based on the Price/Forward Earnings ratio.
CRMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.43.
Industry RankSector Rank
PE 56.16
Fwd PE 7.91
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CRMD's earnings are expected to grow with 101.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y159.5%
EPS Next 3Y101.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (5/21/2025, 2:25:09 PM)

12.355

-0.46 (-3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners37.46%
Inst Owner Change-0.54%
Ins Owners1.84%
Ins Owner Change7.31%
Market Cap837.79M
Analysts83.33
Price Target15.81 (27.96%)
Short Float %12.68%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)53.18%
Min EPS beat(2)52.29%
Max EPS beat(2)54.06%
EPS beat(4)4
Avg EPS beat(4)30%
Min EPS beat(4)1.96%
Max EPS beat(4)54.06%
EPS beat(8)5
Avg EPS beat(8)11.78%
EPS beat(12)8
Avg EPS beat(12)12.17%
EPS beat(16)10
Avg EPS beat(16)10.32%
Revenue beat(2)2
Avg Revenue beat(2)9.47%
Min Revenue beat(2)3.62%
Max Revenue beat(2)15.32%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.32%
EPS NQ rev (1m)6.12%
EPS NQ rev (3m)71.81%
EPS NY rev (1m)17.23%
EPS NY rev (3m)38.94%
Revenue NQ rev (1m)2.64%
Revenue NQ rev (3m)18.81%
Revenue NY rev (1m)10.24%
Revenue NY rev (3m)11.21%
Valuation
Industry RankSector Rank
PE 56.16
Fwd PE 7.91
P/S 19.27
P/FCF N/A
P/OCF N/A
P/B 9.9
P/tB 10.12
EV/EBITDA N/A
EPS(TTM)0.22
EY1.78%
EPS(NY)1.56
Fwd EY12.65%
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.64
BVpS1.25
TBVpS1.22
PEG (NY)0.16
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.09%
ROE -21.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.66%
FCFM N/A
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.35%
Cap/Sales 0.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.16
Altman-Z 11.82
F-Score3
WACC9.85%
ROIC/WACCN/A
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%220%
EPS Next Y346.76%
EPS Next 2Y159.5%
EPS Next 3Y101.76%
EPS Next 5Y52.64%
Revenue 1Y (TTM)N/A
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%N/A
Revenue Next Year265.42%
Revenue Next 2Y136.58%
Revenue Next 3Y90.53%
Revenue Next 5Y48.61%
EBIT growth 1Y54.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year305.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-30.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.78%
OCF growth 3YN/A
OCF growth 5YN/A